Clinical Management of Episodic Memory Changes in Dementia

  • Po-Heng TsaiEmail author
Dementia (J Pillai, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Dementia


Purpose of review

The purpose of this review was to discuss therapeutic options available for the treatment of memory difficulties in dementia.

Recent findings

Because of the lack of progress in the availability of new medications, there has been an increased interest in focusing on non-pharmacological means to management cognitive symptoms related to dementia.


The clinical management of memory loss should focus both on pharmacological and non-pharmacological approaches. Treatment with medications should usually begin with a cholinesterase inhibitor and then followed by addition of memantine if there is a decline. In addition to medication management, emphasis should be placed on the importance of maintaining a healthy lifestyle that encompasses physical activities, cognitive stimulation, and a healthy diet.


Dementia Alzheimer’s disease Treatment Non-pharmacological Physical activities Mediterranean diet 


Compliance with Ethical Standards

Conflict of Interest

The author declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    American Psychiatric Association, American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013.Google Scholar
  2. 2.
    Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2017. 2017;13(3):325–73.Google Scholar
  3. 3.
    Budson AE, Price BH. Memory dysfunction. NEJM. 2005;352:692–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004;55(6):815–28.CrossRefPubMedGoogle Scholar
  5. 5.
    Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Villarroya M, García AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer’s disease. Curr Pharm Des 2004;10(25):3177–3184.Google Scholar
  7. 7.
    Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.Google Scholar
  8. 8.
    Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–25.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhu CW, Livote EE, Scarmeas N, Albert M, Brandt J, Blacker D, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer’s disease. Alzheimers Dement. 2013;9(6):733–40.Google Scholar
  10. 10.
    Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc. 2003 Jul;51(7):937–44.CrossRefPubMedGoogle Scholar
  11. 11.
    Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009 May;24(5):479–88.Google Scholar
  12. 12.
    Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004 Jun 26;363(9427):2105–15.CrossRefPubMedGoogle Scholar
  13. 13.
    Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015 Dec;14(12):1171–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Alva G, Cummings JL. Relative tolerability of Alzheimer’s disease treatments. Psychiatry (Edgmont). 2008;5(11):27–36.Google Scholar
  15. 15.
    Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8):707–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer’s disease. Curr Med Res Opin. 2005;21(11):1809–18.Google Scholar
  17. 17.
    O’Regan J, Lanctôt KL, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015 Nov;76(11):e1424–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003 Fall;9(3):275–308.CrossRefPubMedGoogle Scholar
  19. 19.
    Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61–74.PubMedGoogle Scholar
  20. 20.
    McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006 19;(2):CD003154.Google Scholar
  21. 21.
    Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):263–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83–9.CrossRefPubMedGoogle Scholar
  25. 25.•
    Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6. eCollection 2013. This meta-analysis supports the use of combination therapy of cholinesterase inhibitor and memantine.
  26. 26.
    Davenport MH, Hogan DB, Eskes GA, Longman RS, Poulin MJ. Cerebrovascular reserve: the link between fitness and cognitive function? Exerc Sport Sci Rev. 2012;40(3):153–8.PubMedGoogle Scholar
  27. 27.
    Erickson KI, Weinstein AM, Lopez OL. Physical activity, brain plasticity, and Alzheimer’s disease. Arch Med Res. 2012;43(8):615–21.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Raji CA, Merrill DA, Eyre H, Mallam S, Torosyan N, Erickson KI, et al. Longitudinal relationships between caloric expenditure and gray Matter in the Cardiovascular Health Study. J Alzheimers Dis. 2016;52(2):719–29.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Dougherty RJ, Schultz SA, Kirby TK, Boots EA, Oh JM, Edwards D, et al. Moderate physical activity is associated with cerebral glucose metabolism in adults at risk for Alzheimer’s Disease. J Alzheimers Dis. 2017;58(4):1089–97.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD006489. DOI:
  31. 31.
    Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in Alzheimer’s disease: a systematic review. Int Psychogeriatr. 2014;26(1):9–18.PubMedGoogle Scholar
  32. 32.
    Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD003260. DOI:
  33. 33.
    Buschert V, Bokde AL, Hampel H. Cognitive intervention in Alzheimer disease. Nat Rev. Neurol. 2010;6:508–17.CrossRefPubMedGoogle Scholar
  34. 34.
    Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD005562. DOI:
  35. 35.
    Huntley JD, Gould RL, Liu K, Smith M, Howard RJ. Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. BMJ Open. 2015;5:e005247. Scholar
  36. 36.
    Graessel E, Stemmer R, Eichenseer B, et al. Non-pharmacological, multicomponent group therapy in patients with degenerative dementia: a 12-month randomizied, controlled trial. BMC Med. 2011 Dec 1;9:129. Scholar
  37. 37.
    Lauenroth A, Ioannidis AE, Teichmann B. Influence of combined physical and cognitive training on cognition: a systematic review. BMC Geriatr. 2016 Jul 18;16:141.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.•
    Shimada H, Makizako H, Doi T, Park H, Tsutsumimoto K, Verghese J, et al. Effects of combined physical and cognitive exercises on cognition and mobility in patients with mild cognitive impairment: a randomized clinical trial. J Am Med Dir Assoc. 2017 Nov 16. pii: S1525–8610(17)30542-X. doi: This recent randomized clinical trial demonstrated benefits of combined physical and cognitive activities in cognition in subjects with mild cognitive impairment.
  39. 39.
    Hardman RJ, Kennedy G, Macpherson H, Scholey AB, Pipingas A. Adherence to a Mediterranean-style diet and effects on cognition in adults: a qualitative evaluation and systematic review of longitudinal and prospective trials. Front Nutr. 2016;3:22. eCollection 2016CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    • Petersson SD, Philippou E. Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence. Adv Nutr. 2016;7(5):889–904. This recent systemic review provides a good summary and overview of Mediterranean diet and cognition.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Gu Y, Brickman AM, Stern Y, Habeck CG, Razlighi QR, Luchsinger JA, et al. Mediterranean diet and brain structure in a multiethnic elderly cohort. Neurology. 2015;85(20):1744–51.Google Scholar
  42. 42.
    Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol. 2006;63(12):1709–17.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Widmer RJ, Flammer AJ, Lerman LO. Lerman A3. The Mediterranean diet, its components, and cardiovascular disease. Am J Med. 2015 Mar;128(3):229–38.CrossRefPubMedGoogle Scholar
  44. 44.
    • Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63. This is one of the largest randomized controlled trial that showed a multimodal approach including diet, exercise, and cognitive stimulation could maintain or improve cognitive function in at risk subjects.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Cleveland Clinic Lou Ruvo Center for Brain HealthWestonUSA

Personalised recommendations